Last reviewed · How we verify
NCT06095557
MCG Discovery Study in Emergency Departments
NA trial testing Sponsor MCG device in ACS - Acute Coronary Syndrome in 124 participants. Completed in 8 July 2025.
9 June 2025
Quick facts
| Lead sponsor | SB Technology, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 124 |
| Start date | 30 October 2023 |
| Primary completion | 9 June 2025 |
| Estimated completion | 8 July 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sponsor MCG device
Conditions studied
- ACS - Acute Coronary Syndrome — all drugs for ACS - Acute Coronary Syndrome →
- NSTEMI - Non-ST Segment Elevation MI — all drugs for NSTEMI - Non-ST Segment Elevation MI →
Sponsor
SB Technology, Inc.
Who can join
18 and older, any sex, with ACS - Acute Coronary Syndrome or NSTEMI - Non-ST Segment Elevation MI. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting. The main question it aims to answer is whether interpretable data can be reliably collected as part of an ED workflow.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06095557
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ACS - Acute Coronary Syndrome
Currently open trials in the same condition.
- NCT07064109 — Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients · NA · recruiting
- NCT07283809 — European Unified Registries for Heart Care Evaluation and Randomised Trials Italy · recruiting
- NCT06283888 — CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention · Phase 4 · recruiting
Other SB Technology, Inc. trials
Trials by the same sponsor.
- NCT06620744 — Magnetocardiography (MCG) Device Use in Patients With Elevated Troponin · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06095557 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SB Technology, Inc.
- Last refreshed: 21 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06095557.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing